Cat. No.: HY-N0877

Bufalin

Name: Bufalin
Brand: MedChemExpress
SKU: HY-N0877
Price: 60.00 USD
Availability: InStock
Rating: 5 (12 reviews)

12 Cited Publications

고객리뷰

Based on 12 publication(s) in Google Scholar

Bufalin is an active component isolated from Chan Su, acts as a potent Na⁺/K⁺-ATPase inhibitor, binds to the subunit α1, α2 and α3, with K_d of 42.5, 45 and 40 nM, respectively. Anti-cancer activity.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.86%
CAS No.: 465-21-4
화학식: C₂₄H₃₄O₄
분자량:386.52

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Bufalin Chemical Structure

CAS No.: 465-21-4

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (12)
용액&용해도
- In Vitro
- In Vivo
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target

Kd: 42.5 nM (Na,K-ATPase α1), 45 nM (Na,K-ATPase α2), 40 nM (Na,K-ATPase α3)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	EC₅₀	7.5 nM Compound: 4	Cytotoxicity against human 786-O cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against human 786-O cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 30369239]
A549	IC₅₀	0.6 μM Compound: 7	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 24050254]
Bel-7402	IC₅₀	7 nM Compound: 1	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 15844967]
Bel-7402	IC₅₀	7 x 10^-3 μM Compound: 1	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 15844967]
Bel-7402	IC₅₀	7*10^-3 μmol/L Compound: 1	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 15844967]
BGC-823	IC₅₀	4.5 x 10^-2 μM Compound: 1	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 15844967]
BGC-823	IC₅₀	4.5*10^-2 μmol/L Compound: 1	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 15844967]
BGC-823	IC₅₀	0.99 μM Compound: 6, bufalin	Cytotoxicity against human BGC823 cells Cytotoxicity against human BGC823 cells	[PMID: 17911017]
BGC-823	IC₅₀	0.99 μM/L Compound: 6, bufalin	Cytotoxicity against human BGC823 cells Cytotoxicity against human BGC823 cells	[PMID: 17911017]
BXPC-3	EC₅₀	11 nM Compound: 4	Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 30369239]
CCRF S-180	IC₅₀	>50 μM Compound: 1	Cytotoxicity against mouse S180 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against mouse S180 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23799775]
CCRF S-180	EC₅₀	>20000 nM Compound: 4	Cytotoxicity against mouse S180 cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against mouse S180 cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 30369239]
CNE	IC₅₀	0.279 μM Compound: 1	Cytotoxicity against human CNE1 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human CNE1 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23799775]
CNE2Z	IC₅₀	0.46 μM Compound: 1	Cytotoxicity against human CNE2Z cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human CNE2Z cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23799775]
H22	IC₅₀	>50 μM Compound: 1	Cytotoxicity against mouse H22 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against mouse H22 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23799775]
HCT-116	EC₅₀	11 nM Compound: 4	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 30369239]
HeLa	IC₅₀	2.8 x 10^-2 μM Compound: 1	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 15844967]
HeLa	IC₅₀	2.8*10^-2 μmol/L Compound: 1	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 15844967]
HeLa	IC₅₀	0.73 μM Compound: 6, bufalin	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 17911017]
HeLa	IC₅₀	0.73 μM/L Compound: 6, bufalin	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 17911017]
HeLa	IC₅₀	279.9 nM Compound: Bufalin	Cytotoxicity activity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30245398]
HeLa	IC₅₀	594.2 nM Compound: Bufalin	Cytotoxicity activity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity activity against human HeLa cells after 24 hrs by MTT assay	[PMID: 30245398]
HepG2	IC₅₀	0.64 μM Compound: 6, bufalin	Cytotoxicity against human HepG2 cells Cytotoxicity against human HepG2 cells	[PMID: 17911017]
HepG2	IC₅₀	0.64 μM/L Compound: 6, bufalin	Cytotoxicity against human HepG2 cells Cytotoxicity against human HepG2 cells	[PMID: 17911017]
HepG2	IC₅₀	0.345 μM Compound: 1	Cytotoxicity against adriamycin-resistant human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against adriamycin-resistant human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23799775]
HepG2	IC₅₀	0.589 μM Compound: 1	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23799775]
HepG2	IC₅₀	0.6 μM Compound: 7	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 24050254]
HepG2	EC₅₀	35 nM Compound: 4	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 30369239]
HL-60	IC₅₀	<0.01 μg/mL Compound: 16	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 11575946]
HUVEC	EC₅₀	12 nM Compound: 4	Cytotoxicity against human HUVEC cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against human HUVEC cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 30369239]
KB	IC₅₀	0.67 μg/mL Compound: 16	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 11575946]
MCF7	EC₅₀	42 nM Compound: 4	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 30369239]
MES-SA	EC₅₀	28 nM Compound: 4	Cytotoxicity against human MESSA cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against human MESSA cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 30369239]
MES-SA/Dx5	EC₅₀	18 nM Compound: 4	Cytotoxicity against human MES-SA/Dx5 cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against human MES-SA/Dx5 cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 30369239]
MH60	IC₅₀	>25 μg/mL Compound: 16	Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay	[PMID: 11575946]
MH60	IC₅₀	>64.8 μM Compound: 3	Growth inhibition of IL-6-independent mouse MH60 cells after 72 hrs by MTT assay Growth inhibition of IL-6-independent mouse MH60 cells after 72 hrs by MTT assay	[PMID: 15620253]
MH60	IC₅₀	31.9 μM Compound: 3	Growth inhibition of IL6-dependent mouse MH60 cells after 72 hrs by MTT assay in presence of human recombinant IL6 Growth inhibition of IL6-dependent mouse MH60 cells after 72 hrs by MTT assay in presence of human recombinant IL6	[PMID: 15620253]
NCI-H1975	EC₅₀	13 nM Compound: 4	Cytotoxicity against human NCI-H1975 cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against human NCI-H1975 cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 30369239]
SK-OV-3	EC₅₀	10 nM Compound: 4	Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 30369239]
U-87MG ATCC	EC₅₀	14 nM Compound: 4	Cytotoxicity against human U87MG cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against human U87MG cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 30369239]

In Vitro

Bufalin (0, 1, 2, 4 μM for 48 hours) decreases cell viability in NCI-H460 cells^[2].
Bufalin (2 μM) increases caspae-3, Endo G and GADD153 mRNA expression, but decreases the GRP78 mRNA expression^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

NCI-H460 cells
Concentration:

0, 1, 2, 4 μM
Incubation Time:

48 hours
Result:

Decreased viability of NCI-H460 cells in a dose-dependent manner.

In Vivo

Bufalin (0.1, 0.2, or 0.4 mg/kg, i.p., daily for 14 days) shows significant anti-tumor activity in mice bearing NCI-H460 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Forty male athymic BALB/c nu/nu mice (6-8 weeks old)^[2]
Dosage:

0.1, 0.2, or 0.4 mg/kg
Administration:

I.P. every day until 14 days
Result:

Dose-dependently suppressed tumor growth.

Chemical Information

CAS No. 465-21-4
Appearance Solid
분자량 386.52
화학식 C₂₄H₃₄O₄
Color White to off-white
SMILES

O[C@]([C@@](CC[C@@]1([H])[C@@]2(CC[C@H](O)C1)C)([H])[C@]2([H])CC3)(CC[C@@H]4C(C=C5)=COC5=O)[C@]34C
Structure Classification
- Steroids
Initial Source
- Animals
toad
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (12)

All Cell Proliferation/Viability AssayWBCell Migration/Invasion AssayIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Pharmacol Res

Small molecule targeting topoisomerase 3β for cancer therapy. [Abstract]

2021 Dec:174:105927. PMID: 34740818

Bufalin purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2021 Dec:174:105927. [Abstract]

CCK8 assay of HCT116 cells upon Bufalin (BFL) (0-0.3 μM; 24 h) treatment at indicated doses.

Bufalin purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2021 Dec:174:105927. [Abstract]

Bufalin (BFL) (0.03-0.3 μM; 24 h) caused TOP3β depletion in HCT116 cells.
Apoptosis

Bufalin targeting BFAR inhibits the occurrence and metastasis of gastric cancer through PI3K/AKT/mTOR signal pathway. [Abstract]

2023 Oct;28(9-10):1390-1405. PMID: 37253905

Bufalin purchased from MedChemExpress. Usage Cited in: Apoptosis. 2023 Oct;28(9-10):1390-1405. [Abstract]

Bufalin (12.5, 25, 50, 100, 200 nM; 24, 48, 72 h) significantly reduces the viability of MKN-45 and HGC-27 GC cells in a dose- and time-dependent manner.

Bufalin purchased from MedChemExpress. Usage Cited in: Apoptosis. 2023 Oct;28(9-10):1390-1405. [Abstract]

Bufalin (20-80 nM; 12-24 h) significantly inhibited the migration ability of MKN-45 and HGC-27 GC cell lines in a dose-dependent manner.

Bufalin purchased from MedChemExpress. Usage Cited in: Apoptosis. 2023 Oct;28(9-10):1390-1405. [Abstract]

Bufalin (1 mg/kg; 100 μL; i.p.; every two days for 2–3 weeks) significantly decreased the tumor volume of gastric cancer (GC) xenograft mice.
Int J Mol Med

Bufalin exerts antitumor effects in neuroblastoma via the induction of reactive oxygen species‑mediated apoptosis by targeting the electron transport chain. [Abstract]

2020 Dec;46(6):2137-2149. PMID: 33125107
J Ethnopharmacol

Integrated network pharmacology, proteomics, molecular docking, and experiments in vivo and in vitro to explore the efficacy and potential mechanism of bufalin against hepatocellular carcinoma angiogenesis. [Abstract]

2025 Apr 9:345:119589. PMID: 40057142
Biochem Pharmacol

Bufalin reverses oxaliplatin resistance in gastric cancer by targeting YBX1 to suppress glycolysis. [Abstract]

2026 Apr 15;250(Pt 1):117976. PMID: 41991006
Int J Pharm

2026 Jul 27:702:127241. PMID: 42508509
Int J Mol Sci

Bufalin Suppresses Pancreatic Ductal Adenocarcinoma Through ER Stress-Ferroptosis Crosstalk Associated with IP3R-Linked Ca2+ Dysregulation and ATF3/SLC7A11 Regulation. [Abstract]

2026 May 14;27(10):4373. PMID: 42196362
Int J Mol Sci

Bufalin Inhibits Tumorigenesis, Stemness, and Epithelial-Mesenchymal Transition in Colorectal Cancer through a C-Kit/Slug Signaling Axis. [Abstract]

2022 Nov 1;23(21):13354. PMID: 36362141
Cancers (Basel)

Identification of Cardiac Glycosides as Novel Inhibitors of eIF4A1-Mediated Translation in Triple-Negative Breast Cancer Cells. [Abstract]

2020 Aug 4;12(8):2169. PMID: 32759815
Chem Res Toxicol

Cardiac Glycoside Compound Isolated from Helleborus thibetanus Franch Displays Potent Toxicity against HeLa Cervical Carcinoma Cells through ROS-Independent Autophagy. [Abstract]

2019 Dec 16;32(12):2479-2487. PMID: 31714069
Vet Microbiol

Identification and evaluation of Nordihydroguaiaretic acid (NDGA) as an active traditional Chinese medicine compound inhibiting the 3C-like protease of feline infectious peritonitis virus. [Abstract]

2025 Sep 15:310:110730. PMID: 40976146
J Assist Reprod Genet

FXYD1 was identified as a hub gene in recurrent miscarriage and involved in decidualization via regulating Na/K-ATPase activity. [Abstract]

2025 Feb;42(2):665-678. PMID: 39730944

용액&용해도

In Vitro:

DMSO : 100 mg/mL (258.72 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5872 mL

12.9359 mL

25.8719 mL

5 mM

0.5174 mL

2.5872 mL

5.1744 mL

10 mM

0.2587 mL

1.2936 mL

2.5872 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (291 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Katz A, et al. Selectivity of digitalis glycosides for isoforms of human Na,K-ATPase. J Biol Chem. 2010 Jun 18;285(25):19582-92. [Content Brief]

[2]. Wu SH, et al. Bufalin induces apoptosis in vitro and has Antitumor activity against human lung cancer xenografts in vivo. Environ Toxicol. 2017 Apr;32(4):1305-1317. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5872 mL	12.9359 mL	25.8719 mL	64.6797 mL
	5 mM	0.5174 mL	2.5872 mL	5.1744 mL	12.9359 mL
	10 mM	0.2587 mL	1.2936 mL	2.5872 mL	6.4680 mL
	15 mM	0.1725 mL	0.8624 mL	1.7248 mL	4.3120 mL
	20 mM	0.1294 mL	0.6468 mL	1.2936 mL	3.2340 mL
	25 mM	0.1035 mL	0.5174 mL	1.0349 mL	2.5872 mL
	30 mM	0.0862 mL	0.4312 mL	0.8624 mL	2.1560 mL
	40 mM	0.0647 mL	0.3234 mL	0.6468 mL	1.6170 mL
	50 mM	0.0517 mL	0.2587 mL	0.5174 mL	1.2936 mL
	60 mM	0.0431 mL	0.2156 mL	0.4312 mL	1.0780 mL
	80 mM	0.0323 mL	0.1617 mL	0.3234 mL	0.8085 mL
	100 mM	0.0259 mL	0.1294 mL	0.2587 mL	0.6468 mL

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Bufalin

Publications Citing Use of MedChemExpress (MCE) Bufalin